Hims & Hers is the largest telehealth company in the US with $2.35B in 2025 revenue. They also confirmed a data breach on April 2, 2026, received an FDA warning letter in September 2025, have no Spanish-language support, and charge $1,899/month for tirzepatide access. This page compares REMEVi and Hims & Hers across every dimension that matters for GLP-1 semaglutide patients in 2026.
Hims & Hers is the most recognizable GLP-1 telehealth brand — but recognition isn't the same as trust or value. REMEVi offers compounded semaglutide for $130/month less than Hims' equivalent, includes full bilingual English/Spanish support Hims has never built, and has a clean data security record. If you speak Spanish, are cost-conscious, or are newly concerned about Hims' data breach, the comparison tilts decisively toward REMEVi.
Hims & Hers confirmed a data breach affecting patient data including personal and potentially medical information. This breach occurred just months after their rapid GLP-1 expansion. REMEVi has had zero data breaches.
The FDA issued a warning letter to Hims & Hers for misleading claims about their compounded GLP-1 medications. This is the same category of violation for which MEDVi received a warning letter in February 2026.
A consistent customer complaint across Reddit, Trustpilot, and BBB reviews: Hims sends an extraordinary volume of marketing communications — some patients report 15–20 per day. The unsubscribe process is reported as difficult.
Hims & Hers Mounjaro/Zepbound access costs $1,899/month — among the highest in the industry. Their no-refund policy and aggressive marketing tactics have generated significant BBB and consumer complaints.
| Category | REMEVi | Hims & Hers |
|---|---|---|
| Compounded semaglutide | $169 intro / $279/mo — all-inclusive | Wegovy Pill $149/mo; injectable varies |
| Tirzepatide access | $289 intro / $369/mo compounded | $1,899/mo for Mounjaro/Zepbound |
| All-inclusive pricing | Yes — one price, no surprises | Often billed separately; complaints about hidden costs |
| Spanish language support | Full bilingual English + Spanish | English only |
| Data security | Zero breaches. HIPAA certified. | Confirmed breach April 2, 2026 |
| FDA compliance | LegitScript certified. No warnings. | FDA warning letter September 2025 |
| Marketing communications | Relevant health updates only | 15–20 emails/day reported by patients |
| Refund policy | Transparent refund policy | No refund policy widely reported |
| Women's health | GLP-1, HRT, hair, skin, mental health | Hers brand — criticized as Hims rebranded |
| Cancellation | One-click, instant | Process reported as difficult by some users |
| Human support | Bilingual coordinators, 2-hr response | Customer service varies by report |
| Brand recognition | Growing — new platform | Largest US telehealth platform $2.35B revenue |
Hims & Hers advertises compounded semaglutide starting at $149/month. However, the actual all-in cost depends on which product and dose you need:
For tirzepatide specifically, REMEVi is approximately $1,500/month less expensive than Hims & Hers. Even for semaglutide, REMEVi delivers the same compounded medication with bilingual support for less per month.
Hims & Hers spent $2.35 billion in revenue in 2025. They have a dedicated women's health brand (Hers), a skincare line, a hair loss program, and an erectile dysfunction vertical. They have never built a single page in Spanish.
There are 65 million Spanish-speaking adults in the United States. The obesity rate among Hispanic adults is among the highest of any demographic group. Less than 10% have ever used a prescription weight loss medication. The barrier is not lack of interest — it's lack of a platform that speaks their language.
REMEVi is the first GLP-1 telehealth platform built bilingual-first. Every piece of Hims' $2.35B revenue infrastructure is English-only. That's a market failure REMEVi was built to fix.
Compounded semaglutide from $169/mo. Tirzepatide from $289/mo. Bilingual English/Spanish. Zero data breaches.
Get started with REMEVi →Disclaimer: Based on publicly available data, FDA records, consumer reviews, and company disclosures as of April 2026. REMEVi is not affiliated with Hims & Hers Health Inc. or its subsidiaries. All pricing should be verified directly with providers before making healthcare decisions. This is for informational purposes only and does not constitute medical advice.